HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...

Purpose: The pharmacology, efficacy, and safety of etravirine and its clinical utility with respect to the available alternative human immunodeficiency virus (HIV) treatment options are reviewed.

The development of new classes of antiretroviral drugs, such as integrase inhibitors and CCR5-antagonistic entry inhibitors, has opened the possibility of considering regimens without NRTIs (Table 1).

Background. Human immunodeficiency virus (HIV)-infected patients on combination active antiretroviral therapy (cART) are at increased risk of age-related complications. We hypothesized that ...

Switching to integrase strand transfer inhibitors (INSTI) from protease inhibitors is associated with new diabetes risk in people with HIV, according to a study published online March 27 in The Lancet ...

Many cancers exhibit high levels of the reverse transcriptase enzyme. Single-agent lamivudine, a reverse transcriptase inhibitor, stopped disease progression in over 25% of patients with fourth-line ...

In a new Johns Hopkins Medicine study funded by the National Institutes of Health, researchers found adults with HIV who switched from protease inhibitors to integrase inhibitors were at increased ...

The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and ...

Diabetes mellitus affects more than 10% of people with HIV, and its incidence is rising as the population ages, according to the National Institutes of Health. Antiretroviral therapies that treat HIV ...

HIV-1 reverse transcriptase inhibitors remain a cornerstone of antiretroviral therapy, targeting the enzyme responsible for converting viral RNA into DNA. This class of drugs, particularly nucleoside ...